# A Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept

> **NCT01339481** · — · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 26 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** abatacept

## Key facts

- **NCT ID:** NCT01339481
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2011-11-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01339481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01339481, "A Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01339481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*